380 related articles for article (PubMed ID: 20215553)
21. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
22. Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.
Lee DW; Han SW; Cha Y; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Park JW; Ryoo SB; Jeong SY; Kang GH; Park KJ; Kim TY
BMC Cancer; 2015 Oct; 15():690. PubMed ID: 26467912
[TBL] [Abstract][Full Text] [Related]
23. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.
Gennari A; Nanni O; Puntoni M; DeCensi A; Scarpi E; Conte P; Antonucci G; Amadori D; Bruzzi P
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1862-7. PubMed ID: 23945199
[TBL] [Abstract][Full Text] [Related]
24. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
de Azambuja E; McCaskill-Stevens W; Francis P; Quinaux E; Crown JP; Vicente M; Giuliani R; Nordenskjöld B; Gutiérez J; Andersson M; Vila MM; Jakesz R; Demol J; Dewar J; Santoro A; Lluch A; Olsen S; Gelber RD; Di Leo A; Piccart-Gebhart M
Breast Cancer Res Treat; 2010 Jan; 119(1):145-53. PubMed ID: 19731015
[TBL] [Abstract][Full Text] [Related]
25. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
[TBL] [Abstract][Full Text] [Related]
26. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Meyerhardt JA; Tepper JE; Niedzwiecki D; Hollis DR; McCollum AD; Brady D; O'Connell MJ; Mayer RJ; Cummings B; Willett C; Macdonald JS; Benson AB; Fuchs CS
J Clin Oncol; 2004 Feb; 22(4):648-57. PubMed ID: 14966087
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
29. Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer.
Alipour S; Kennecke HF; Woods R; Lim HJ; Speers C; Brown CJ; Gill S; Renouf DJ; Cheung WY
J Gastrointest Cancer; 2013 Jun; 44(2):203-10. PubMed ID: 23264206
[TBL] [Abstract][Full Text] [Related]
30. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
Iwashyna TJ; Lamont EB
J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
[TBL] [Abstract][Full Text] [Related]
32. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
33. Severe Obesity Impacts Recurrence-Free Survival of Women with High-Risk Endometrial Cancer: Results of a French Multicenter Study.
Canlorbe G; Bendifallah S; Raimond E; Graesslin O; Hudry D; Coutant C; Touboul C; Bleu G; Collinet P; Darai E; Ballester M
Ann Surg Oncol; 2015 Aug; 22(8):2714-21. PubMed ID: 25503347
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant therapy for colon cancer].
Lordick F; Rosenberg R; Stein HJ; Peschel C; Siewert JR
Dtsch Med Wochenschr; 2004 Oct; 129(44):2366-71. PubMed ID: 15497107
[No Abstract] [Full Text] [Related]
35. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
36. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
37. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
Meyerhardt JA; Niedzwiecki D; Hollis D; Saltz LB; Hu FB; Mayer RJ; Nelson H; Whittom R; Hantel A; Thomas J; Fuchs CS
JAMA; 2007 Aug; 298(7):754-64. PubMed ID: 17699009
[TBL] [Abstract][Full Text] [Related]
38. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
Berger AC; Sigurdson ER; LeVoyer T; Hanlon A; Mayer RJ; Macdonald JS; Catalano PJ; Haller DG
J Clin Oncol; 2005 Dec; 23(34):8706-12. PubMed ID: 16314630
[TBL] [Abstract][Full Text] [Related]
39. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
40. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]